Thick primary melanoma has a heterogeneous tumor biology: an institutional series by Meguerditchian, Ari-Nareg et al.
RESEARCH Open Access
Thick primary melanoma has a heterogeneous
tumor biology: an institutional series
Ari-Nareg Meguerditchian
1*†, Kobby Asubonteng
2†, Calvin Young
3†, Bethany Lema
3†, Gregory Wilding
2† and
John M Kane III
4†
Abstract
Background: Thick melanomas (TM) ≥4 mm have a high risk for nodal and distant metastases. Optimal surgical
management, prognostic significance of sentinel node biopsy (SLNB), and benefits of interferon (IFN) for these
patients are unclear. As a continuum of increasing tumor thickness is placed into a single TM group, differences in
biologic and clinical behavior may be lost. The purpose of this study was to better characterize the diverse biology
in TM, including the value of increasing thickness and nodal status information, potentially identifying high risk TM
subgroups that may warrant more aggressive treatment/follow up.
Methods: 155 consecutive TM patients treated at a single institution between 1971 and 2007 were retrospectively
reviewed. Patient, disease and treatment features were analyzed with respect to disease-free (DFS) and overall
survival (OS).
Results: Median patient age was 66 years and 68% of patients were men. The trunk was the most common TM
location (35%), followed by the head and neck (29%) and lower extremities (20%). Median thickness was 6 mm
and 61% were ulcerated. 6% patients had stage IV disease, 12% had clinical nodal metastases. Clinically negative
lymph node basins were treated by observation (22 patients - 15.4%), elective lymph node dissection (ELND) (24
patients - 17.6%) or SLNB (91 patients - 67%). 75% of ELND’s and 53% of SLNB’s were positive. Completion node
dissection was performed in 38 SLNB+ patients and 22% had additional positive nodes. 17% of the study patients
received IFN. At median follow up of 26 months, 5 year DFS and OS were 42% and 43.6%. For SLNB positive vs
negative, median DFS were 22 vs 111 months (p = 0.006) and median OS were 41 vs 111 months (p = 0.006).
When stratified by tumor thickness ≤ vs > 6 mm, 5 year DFS was 58.3% vs 20% (p < 0.0001) and OS was 62% vs
20% (P < 0.0001). IFN had no impact on DFS or OS (p = 0.98 and 0.8 respectively).
Conclusion: Within the high risk group of patients with TM, cases with tumor thickness > 6 mm or a positive
SLNB had a significantly worse DFS and OS (p < .0001, <.0001 and .006, .006).
Introduction
Approximately 5% of newly diagnosed melanomas will
have a Breslow thickness ≥ 4m m( t h i c km e l a n o m a s ,
TM) [1]. As the risk of nodal metastases correlates with
primary tumor thickness, 40% of TM patients will
develop nodal disease [2]. Increasing tumor thickness is
also associated with a higher rate of distant metastases
and worse survival, with reported 5 and 10 year overall
survival (OS) for TM of 45-79% and 32-44%, respec-
tively [3]. Historically, the role of elective lymph node
dissection (ELND) in the management of TM patients
has been controversial [4-9]. In addition, very few stu-
dies have addressed the prognostic value of sentinel
lymph node biopsy (SLNB) in such a high-risk cohort of
patients [10-16]. Given the high risk for systemic metas-
tases, the role of SLNB in TM remains controversial.
Despite the poor overall outcome for this group, it is
still not clear if the benefits of adjuvant interferon ther-
apy outweigh the potential side effects [17-21]. In fact,
the assumption that patients with TM have a dismal
prognosis has led some to consider any treatment other
than local control to be primarily palliative [2].
The purpose of the American Joint Committee on
Cancer (AJCC) melanoma staging system is to provide
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grouped subsets of patients. In an effort to maintain
simplicity, the continuous variable of tumor thickness
has been converted into categorical variables (< 1 mm,
1.01-2 mm, 2.01-4 mm, > 4 mm) [22]. As a limitation of
this methodology, it is hypothesized that thick primary
tumors (≥ 4 mm) may actually represent a larger and
more diverse group of biologic behaviors as compared
to other primary thickness categories given that the
thickness range (4 to infinity) is much greater than the
1-2 mm intervals in the other groups. Therefore, the
current study examines whether TM has a uniformly
poor prognosis versus a heterogeneous tumor biology
and if nodal status has additional prognostic value in
this high risk subset of patients.
Methods
After Institutional Review Board approval, cases of pri-
mary cutaneous melanoma ≥ 4 mm (TM) treated at Ros-
well Park Cancer Institute between 1971 and 2007 were
identified through the Tumor Registry. Patient demo-
graphic data, clinical tumor features, surgical treatment,
and the final pathology were retrospectively obtained from
the medical record. Information regarding adjuvant ther-
apy, locoregional recurrence, distant relapse, and survival
was extracted from the outpatient follow-up records.
Laboratory tests and imaging were used selectively, based
upon clinical examination and symptoms. Patients under-
went wide excision and those with clinically positive
lymph nodes were treated by therapeutic lymph node dis-
section. Before 1996, patients with clinically negative
lymph node basins were treated by observation or ELND.
After that date, SLNB was the standard of care at Roswell
Park Cancer Institute. Nodal dissections were performed
according to well-described surgical techniques [23].
Lymph node analysis was done by bi-valving nodes identi-
fied in the dissection specimen, whereas sentinel lymph
nodes were analyzed by serial sectioning. Our institution’s
approach has been to present these cases at multidisciplin-
ary tumor conferences. Generally, radiation therapy is
offered to patients with bulky nodes (≥3 cm), nodes show-
ing evidence of extra-capsular invasion or multinodal dis-
ease (≥ 4 nodes). Other than clinical trials, adjuvant
interferon is presented as an option to these patients with
a frank discussion on potential side effects and ambiguity
on certain aspects of treatment benefits. Longitudinal fol-
low up was performed based upon National Comprehen-
sive Cancer Network guidelines [24], with every 3-4
month follow-up until year two, followed by every 6
month visits until year five and annual visits thereafter.
Most patients received their long-term cancer follow-up at
Roswell Park Cancer Institute. For those that did not, the
institutional cancer registry performed annual mailings to
update the records of these patients.
Primary tumor site was defined as: 1) head and neck
(including scalp and cervical areas); 2) trunk (anterior,
posterior and lateral surfaces of chest and abdomen
from the clavicles to the inguinal ligaments); 3) upper
extremity (including the shoulder); and 4) lower extre-
mity (below the inguinal ligament). All patients were
staged using the AJCC 7th edition based upon primary
tumor features, clinical or pathologic regional lymph
node status (where available), and the presence or
absence of distant metastases at the time of initial diag-
nosis. Disease-free survival (DFS) and overall survival
(OS) were calculated from the time of diagnosis until
relapse or death, respectively.
Statistical analysis was performed using SAS 9.1 soft-
ware (SAS Institute, Cary, NC, USA). Descriptive statis-
tics were used to report patients’ baseline characteristics.
Estimation of the overall and disease free survival distri-
butions was done using the Kaplan-Meier method.
Assessment of observed overall group differences in the
survival distributions was done using the log-rank test.
Follow-up testing between pairs of groups was done in
conjunction with a Bonferroni correction. Multivariate
analyses were done using the Cox proportional hazard
model. A 0.05 nominal significance level was used.
Results
Patient and tumor characteristics
One hundred fifty-five patients were identified with TM;
106 males (68%) and 49 females (32%). Median age was
66 years (range 18 - 95 years). The most common pri-
mary tumor site was the trunk (35%) followed by head
and neck (29%), lower extremity (20%), and upper
extremity (16%). Median tumor thickness was 6.0 mm
(range 4.0 - 50.0 mm), mean was 7.8 mm, and 18% of
patients had a primary lesion ≥ 10 mm. Ulceration was
present in 61% of cases and 87% of tumors were Clark
level IV or V. The AJCC stage at presentation is shown
in table 1. Synchronous distant metastases were present
in 6% of TM patients (n = 9). In total, 146 patients
with stage III or lesser TM were offered definitive surgi-
cal therapy.
Table 1 AJCC stage (7
th edition) at presentation (and
following lymph node staging) for patients with thick
melanoma (≥ 4 mm)
AJCC STAGE N (%)
IIB 35 (22.8%)
IIC 46 (29.5%)
IIIA 21 (13.4%)
IIIB 25 (16.1%)
IIIC 19 (12.1%)
IV 9 (6%)
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All patients without distant metastases underwent wide
excision of the primary tumor site as the potentially
curative surgical therapy. Nodal metastatic disease was
clinically obvious at presentation in 12% of patients (n =
9). These patients underwent therapeutic lymph node
dissection. The remaining 137 patients were treated
with nodal basin observation (15.4%), ELND (17.6%) or
SLNB (67%) after 1996. Five patients treated by nodal
basin observation were subsequently diagnosed with
nodal disease, a mean of 20.4 months after having
undergone surgery (range: 4-38). Nodal metastases were
found in 75% (18/24) of the patients undergoing ELND.
Thirty-three percent had only one positive lymph node;
the remainder had 2-6 positive nodes. Fifty-three per-
cent (48/92) of the SLNB patients had a positive sentinel
lymph node. The majority of patients had only one posi-
tive sentinel node, however, 27.5% had ≥ 2 positive sen-
tinel lymph nodes. A completion lymph node dissection
(CLND) was performed in 38 of the positive sentinel
lymph node biopsy patients and 22% had additional
positive nodes (range 1-28) on final pathology. If the
results of ELND and SLNB are combined, 60% (69/115)
of patients with a clinically negative nodal basin had
pathologically confirmed nodal metastatic disease (med-
ian number of positive nodes 1, range 1-28). Due to a
concern for locoregional recurrence, 20% of patients (n
= 29) received adjuvant radiation therapy. Adjuvant
interferon therapy was administered to 17% of patients
(n = 24).
Outcome and survival
Median follow-up was 26 months (range 1-148); 23% of
the study population had a follow-up ≥ 5 years. For the
non-stage IV patients, 47.3% (69/146) developed a recur-
rence. The most common sites of first recurrence were
28.7% primary tumor site/in transit disease, 19.7% regio-
nal lymph node basin, 17.4% pulmonary, 17.4% brain,
10.1% peritoneal surface/abdominal viscera, and 8.7%
bone. DFS at 5 and 10 years were 42% and 23.5%,
respectively. OS at 5 and 10 years were 43.6% and 24%,
respectively. Kaplan-Meier survival curves for DFS and
OS are shown in figure 1.
Differences in DFS and OS were observed based upon
the primary tumor site with the lower extremity having
the most favorable outcome at 5 years (DFS 55%, OS
62%) and the trunk having the worst (DFS 33%, OS
33%). However, these differences did not reach statistical
significance (p = 0.07 for both DFS and OS). As
expected, stage IV patients did the worse, with a mean
survival less than 21 months. However, even within
non-metastatic patients, AJCC stage was a statistically
significant predictor of DFS and OS (table 2). Given that
the median primary tumor thickness was 6 mm, DFS
and OS were reanalyzed based upon two subgroups: ≤ 6
mm (54%) versus > 6 mm (46%). Kaplan-Meier survival
curves for DFS and OS based on these subgroups are
shown in figure 2. Both DFS and OS were statistically
significantly higher in patients with a melanoma ≤ 6
mm versus > 6 mm (table 3). An additional observation
A) 
B) 
Figure 1 Kaplan-Meier survival curves for disease-free survival
(A) and overall survival (B) in patients with thick melanoma (≥
4 mm) .
Table 2 Disease-free and overall survival by AJCC stage
(7
th edition) for non-metastatic patients with thick
melanoma (≥ 4 mm)
AJCC STAGE DISEASE-FREE SURVIVAL OVERALL SURVIVAL
5 year 10 year 5 year 10 year
IIB 56.9% 42.3% 58.2% 43.1%
IIC 42.8% 0% 45.5% 12.1%
IIIA 40.8% 18.2% 54.6% 20.3%
IIIB 30.3% 30.3% 33.0% 33.0%
IIIC 10.0% 0% 13.1% 0%
p value 0.0001 0.0004
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were not the same for both groups, as reflected by 1, 5
and 10 year survival. For TM ≤ 6 mm, over half of
patients were still alive and disease-free at 5 years, but
this number decreased by an additional 50% over the
next 5 years. In contrast, for TM > 6 mm, 80% of
patients died by 5 years with very few additional recur-
rences or deaths after that time. In terms of adjuvant
therapy, interferon had no significant impact on DFS
and OS (p = 0.98 and 0.8, respectively).
DFS and OS were also analyzed based upon a positive
versus negative SLNB in the 92 patients who underwent
this procedure. The presence of a positive SLNB was
significantly associated with an approximately 50%
reduction in DFS and OS at both 5 and 10 years (p
values 0.006 and 0.006, respectively). Survival rates
according to SLNB status as well as the Kaplan-Meier
survival curves are shown in table 4 and figure 3.
Discussion
Many aspects of the optimal curative surgical manage-
ment of melanoma ≥ 4 mm remain to be clarified
[2,8,10,25]. Specifically, only a few publications have
addressed the value of SLNB in this high risk popula-
tion, despite the fact that it is a well-established compo-
nent of the contemporary management of intermediate
thickness melanoma [10-14].
The results of our study challenge the notion that all
patients with TM have uniformly aggressive disease.
Instead, given that this broad group encompasses mela-
noma thickness from 4 mm to infinity (a continuous
variable converted into a categorical variable), one
would expect a heterogeneous tumor biology with dif-
fering prognoses. For the entire group, DFS and OS at
all time points were almost identical. Therefore, clinical
recurrence is usually synonymous with death in this
cohort of patients. However, 5-year OS for patients pre-
senting without metastases was 46-57% and was still a
reasonable 13-55% even in the presence of nodal/lym-
phatic metastases. These outcomes are equivalent or
superior to the 5 year survival rates for primary pan-
creas or esophageal cancer (which are treated very
aggressively from a surgical standpoint). Furthermore,
A) 
B) 
Figure 2 Kaplan-Meier survival curves for disease-free survival
(A) and overall survival (B) in patients with thick melanoma
stratified by primary tumor thickness ≤ 6 mm (group 1) versus
> 6 mm (group 2) .
Table 3 Disease-free and overall survival in patients with
thick melanoma stratified by primary tumor thickness ≤
6 mm versus > 6 mm
DISEASE FREE SURVIVAL
1 year 5 year 10 year
≤ 6m m(54%) 88.4% 58.4% 27.9%
>6m m(46%) 62.9% 19.6% 13.0%
p < 0.0001
OVERALL SURVIVAL
1 year 5 year 10 year
≤ 6m m(54%) 94.9% 62.4% 28.4%
>6m m(46%) 79.6% 20.3% 13.5%
p < 0.0001
Table 4 Disease-free and overall survival in patients with
thick melanoma stratified by a positive versus negative
sentinel lymph node biopsy (n = 92)
DISEASE FREE SURVIVAL OVERALL SURVIVAL
5 year 10 year 5 year 10 year
SLNB + 32% 20% 37% 24%
SLNB - 65% 43% 65% 44%
p = 0.006 p = 0.006
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subsets of ≤ 6 mm versus > 6 mm, differences in biologic
behavior and survival become readily apparent. For
patients with melanoma ≤ 6 mm, the risk of dying was
much lower at 5 years, but did not significantly decrease
over time. In contrast, the vast majority of patients with
melanoma > 6 mm died within the first 5 years with very
few deaths after that point. Given the very early aggres-
sive behavior of “ultra-thick” melanomas (> 6 mm), this
patient population may be the ideal group to study
potential adjuvant systemic therapies as there will be a
significant number of events in a short period of time. In
terms of cancer surveillance, it would be important to
follow the ≤ 6 mm TM patients long-term as they have a
risk for recurrence and death past 5 years that is similar
to patients with intermediate thickness melanoma.
The presence and extent of lymph node metastases is
clearly associated with decreased survival in melanoma
[26]. In the absence of clinically apparent nodal meta-
static disease, SLNB has become the standard approach
for regional lymph node staging. In fact, a positive senti-
nel lymph node biopsy is one of the most powerful pre-
dictors of outcome in melanoma patients [27-29].
Unfortunately, many of the large multi-center SLNB
trials focused mainly on patients with intermediate
thickness tumors (1.01-<4 mm). To date, there have
been few studies that examined the role of SLNB in the
management of TM; 131 patients in Gershenwald et al.,
126 patients in Ferrone et al., and 114 patients in Carl-
son et al [12-14]. These studies were strikingly similar
in terms of patient and tumor characteristics, rates of
SLNB positivity, and survival. In addition, SLNB status
and ulceration were statistically significant independent
predictors of survival with SLNB status being the most
powerful variable. Although thickness stratification was
not examined in Gershenwald et al. and was not asso-
ciated with overall survival in Carlson et al. (82% for ≤6
mm versus 61% for >6 mm, p = 0.085), Ferrone et al.
found that stratified tumor thickness (≤5.5 mm versus
>5.5 mm) and age (<60 versus ≥60) were also indepen-
dent prognostic variables and could be combined with
SLNB status and ulceration to create a prognostic
model. The conclusion in these 3 studies was that SLNB
does have prognostic value in the staging of patients
with TM. In support of the findings from the above stu-
dies, we also found that a positive SLNB was associated
with a significantly increased risk for recurrence and
death (table 4 and figure 2).
A noteworthy observation from our study is that
72.5% of our positive SLNB patients ultimately had only
one positive node and only 22% of the CLND specimens
had additional positive nodes on final pathology. Inter-
estingly, these findings are almost identical to the 70.5%
single positive SLNB rate reported in the Multicenter
Selective Lymphadenectomy Trial-I (MSLT-I) for lower
risk patients with intermediate thickness melanoma
(1.2-3.5 mm)[28]. The rate of additional positive nodes
at CLND for a positive SLNB for Ferrone et al. was 21%
and a similar 16% positive C L N Dr a t ew a ss e e ni nt h e
Sunbelt Melanoma Trial for a much more diverse group
of melanoma patients (tumors ≥1 mm)[14,30]. In addi-
tion, recent data for a subset of TM patients in the Sun-
belt Melanoma Trial also reported no additional positive
nodes in 82% of CLND [31]. Therefore, despite the fact
that TM has been historically associated with an antici-
pated high risk for nodal metastatic disease, it is almost
certainly a more diverse group of tumor biologies with
subsets that may behave akin to lower risk, intermediate
thickness melanomas. Consequently, clinical trials exam-
ining the treatment of nodal metastatic disease and the
efficacy of adjuvant therapies should not exclude TM
patients simply based upon tumor thickness alone.
A) 
B)  
Figure 3 Kaplan-Meier survival curves for disease-free survival
(A) and overall survival (B) in patients with thick melanoma
stratified by a positive (group 1) versus negative (group 2)
sentinel lymph node biopsy .
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study are similar to some of the TM SLNB studies
above, there are several key differences. First, our patient
population contained all patients diagnosed with TM,
including synchronous clinical nodal and distant meta-
static disease. This allows for a broader understanding
of the true “natural history” of patients presenting with
T M .S e c o n d ,o u rr a t eo fS L N Bp o s i t i v i t yw a sh i g h e r
than in the other studies (55% versus 30-39%). However,
this would be anticipated given the fact that we had a
higher risk TM patient population in terms of median
tumor thickness (6 mm versus 5-5.5 mm) as well as
ulceration (61% versus 35.1-50%). Third, as opposed to
looking at SLNB status and ulceration as individual vari-
ables, we incorporated those factors into the patients’
AJCC stage as a way to provide more accurate, clinically
relevant survival information for the clinician treating a
newly diagnosed TM patient. Finally, similar to only
F e r r o n ee ta l . ,w ef o u n dt h a ts t r a t i f i c a t i o nb yt u m o r
thickness (≤6 mm versus >6 mm) was significantly asso-
ciated with both DFS and OS. In fact, it identified what
appears to be two very different tumor biologies as
noted above; an aggressive, “ultra-thick” group that will
succumb to distant metastatic disease within a few years
of diagnosis and a second, somewhat more indolent
group that has a reasonable long-term prognosis but a
prolonged risk for recurrence and death that is similar
to other melanoma thickness subsets.
Controversy surrounding the benefit of adjuvant inter-
feron in “high risk” melanoma patients continues
[7,17,18]. In our study, only 17% of patients received
interferon and this was not associated with a statistically
significant improvement in survival. Lack of a statisti-
cally significant impact on recurrence and death from
melanoma in a similar group of patients has also been
reported by Gajdos et al [32]. Although outside the con-
text of a clinical trial, the survival results reported here
demonstrate that, even within the same high risk group
of patients as defined by tumor thickness ≥4 mm (which
was a cohort in the Eastern Cooperative Oncology
Group EST-1684 study), there was tremendous variabil-
ity in prognosis especially with long-term follow-up. A
prolonged risk of recurrence past 5 years in subsets of
TM patients should be considered when discussing the
potential overall survival benefits of adjuvant interferon.
Conclusion
Significant biologic heterogeneity exists within TM
patients currently defined simply by tumor thickness ≥4
mm. This translates in differences in clinical outcome
both in terms of DFS and OS associated with a threshold
thickness of 6 mm. Patients with “ultra-thick” melanoma
(>6 mm) are at significant risk for early recurrence and
death but may enjoy long-term survival if they make it to
5 years. In contrast, not all patients with a melanoma 4-6
mm thick have limited survival and dismal long-term
prognosis. However, their risk of recurrence continues
past 5 years. SLNB status is a powerful prognostic vari-
able in TM. Consequently, the surgical treatment of
newly diagnosed TM patients without clinical distant
metastatic disease should be identical to that of inter-
mediate thickness melanoma patients; wide excision,
SLNB, and formal lymphadenectomy for either a positive
SLNB or clinically apparent nodal metastatic disease.
One should strongly consider the continuum of thickness
as well as nodal status when assessing TM patients for
adjuvant therapy or designing clinical trials for a “high
risk” melanoma population.
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